Rheos Capital Works’s Madrigal Pharmaceuticals MDGL Stock Holding History

Rheos Capital Works’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.1M	Hold	13,215	–	–	0.4%	72
2026 Q1	$6.92M	Sell	13,215 -13,000	-50%	-$6.21M	0.46%	63
2025 Q4	$15.3M	Sell	26,215 -17,000	-39%	-$8.68M	0.98%	37
2025 Q3	$19.8M	Hold	43,215	–	–	1.11%	40
2025 Q2	$13.1M	Hold	43,215	–	–	0.75%	39
2025 Q1	$14.3M	Sell	43,215 -13,000	-23%	-$4.27M	1.17%	34
2024 Q4	$17.3M	Sell	56,215 -43,000	-43%	-$12.1M	0.96%	38
2024 Q3	$21.1M	Sell	99,215 -11,000	-10%	-$2.81M	1.1%	31
2024 Q2	$30.9M	Hold	110,215	–	–	1.62%	14
2024 Q1	$29.4M	Buy	+110,215	New	+$26M	1.41%	19

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rheos Capital Works's MDGL Position: Q2 2026 in Review

Rheos Capital Works held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 13,215 shares worth $7.1M. The position accounts for 0.4% of the portfolio, ranked #72.

Rheos Capital Works first reported a position in MDGL in Q1 2024 and has held it in 10 quarters since. The position peaked at $30.9M in Q2 2024. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Rheos Capital Works held 13,215 shares of Madrigal Pharmaceuticals worth $7.1M as of Q2 2026.
Rheos Capital Works left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
Madrigal Pharmaceuticals made up 0.4% of Rheos Capital Works's portfolio in Q2 2026, its #72 holding.
Rheos Capital Works first reported a position in Madrigal Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Rheos Capital Works's Madrigal Pharmaceuticals position peaked at $30.9M in Q2 2024.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Rheos Capital Works's 13F filing for Q2 2026, filed 7 Aug 2026.